Core Points - Boralex Inc. announced the upcoming retirement of its Board Chair, Mr. Alain Rhéaume, who will step down once a successor is appointed, no later than December 2025 [1][2] - The selection process for the new Chair will be overseen by the Board's Governance Committee, in line with the company's governance policies [2] - Mr. Rhéaume's retirement follows the release of Boralex's 2030 Strategy, which aims to guide the company's future direction [2][3] - Under Mr. Rhéaume's leadership, Boralex has made significant progress in its strategic directions and governance, which are crucial for stakeholders [3] - The company is well-positioned to capitalize on the strong growth in energy demand and the ongoing energy transition, presenting significant opportunities in the renewable energy sector [4] - Boralex has seen a renewal of its executive team, including the appointment of Patrick Decostre as President and CEO, and welcomed three new directors to enhance the Board's skills [8] - The company has achieved its objectives under the 2025 Strategic Plan and is set to continue its growth trajectory with the newly unveiled 2030 Strategy [8] - Boralex has increased its installed capacity by over 50% to 3.2 GW over the past five years and is developing a project portfolio exceeding 8 GW in wind, solar, and storage [10]

Key Takeaways DOCS grew FY25 revenues 20% to $570.4M and saw free cash flow jump 56%, but guidance lagged expectations. IRTC raised FY25 revenue outlook to $690-$700M following strong growth and key AI-driven clinical validation. IRTC stock soared 61.4% YTD, outpacing DOCS at 6.9%, fueled by innovation in diagnostics and margin gains.As digital health continues to evolve rapidly, Doximity (DOCS) and iRhythm Technologies (IRTC) stand out as two of the most intriguing players in AI-powered healthcare. Doxim ...

Key Takeaways Casgevy, CRSP's first marketed therapy, treats SCD and TDT but saw just $10 million in 2024 sales. The therapy's complex, multi-step process has slowed adoption despite its curative potential. Casgevy faces pressure from cheaper approved drugs and emerging gene-editing competitors.CRISPR Therapeutics’ (CRSP) first marketed product is the one-shot gene therapy Casgevy, approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell dis ...

Core Viewpoint - American Water Works (AWK) is positioned as a strong investment option in the utility sector due to its organic growth, strategic acquisitions, and consistent returns from military contracts [1] Growth Projections - The Zacks Consensus Estimate for AWK's 2025 earnings per share (EPS) is $5.71, reflecting a year-over-year increase of 5.9% [2] - The sales estimate for 2025 is $4.85 billion, indicating a year-over-year increase of 3.6% [2] - AWK's long-term earnings growth rate is projected at 7.4%, with a trailing four-quarter average earnings surprise of 0.8% [2] Debt Position - AWK's total debt to capital ratio stands at 56.05%, which is better than the sector average of 59.23% [3] - The time-to-interest earned ratio is 3.6, indicating the company's strong ability to meet future interest obligations [3] Return on Equity - AWK's return on equity (ROE) is 10.35%, surpassing the sector average of 9.98%, demonstrating efficient capital utilization [4] Dividend History - The company has a consistent history of increasing dividends, with an annual dividend of $3.31 per share and a current dividend yield of 2.35%, outperforming the S&P 500 average of 1.24% [5] Strategic Acquisitions - AWK expanded its customer base through 13 acquisitions in 2024, adding 69,500 customers, with 18 more pending acquisitions expected to add another 37,400 customers [6][8] - The company focuses on acquiring utilities that serve between 5,000 to 50,000 customers [7] Share Price Performance - Year-to-date, AWK's stock has returned 13.4%, compared to the sector's growth of 6.3% [9]

Meta Platforms (NASDAQ: META) is scheduled to distribute its quarterly dividend on June 26. The social media stock has demonstrated strong performance throughout 2025, driven by investor optimism around Meta’s bold push into artificial intelligence infrastructure and its expansion into new advertising channels.META closed Wednesday’s session at $695.77, representing a 16% gain year-to-date and a 0.46% increase over the past week. The performance positions Meta among the top performers in the technology sect ...

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a complaint has been filed in the United States District Court for the Southern District of New York on behalf of investors (the “Class”) who purchased or acquired the securities of Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS) between May 2, 2024 and May 6, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain ...

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Krispy Kreme, Inc. (“Krispy Kreme” or the “Company”) (NASDAQ: DNUT) between February 25, 2025 and May 7, 2025, inclusive. For more information, submit a form at Krispy Kreme, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or c ...

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a complaint has been filed in the United States District of Oregon on behalf of investors (the “Class”) who purchased or acquired the securities of Digimarc Corporation (“Digimarc” or the “Company”) (NASDAQ: DMRC) between May 3, 2024 and February 26, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officer ...

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, inclusive. For more information, submit a form at Rocket Pharmaceuticals, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@ber ...

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a complaint has been filed in the United States District Court for the Southern District of New York on behalf of investors (the “Class”) who purchased or acquired the securities of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Compan ...